CClinicalTrials.gg
TerminatedNCT01267825Updated Aug 31, 2018Results posted

CT Guided Injection for Low Back Radiculopathy: A Randomized Clinical Trial

A Phase 4 interventional study of CT-guided corticosteroid+ bupivicaine and Standard medical care in Disc Herniation and Lumbosacral Radiculopathy, sponsored by Montefiore Medical Center. Terminated at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by Montefiore Medical Center · Phase 4, Interventional, and Treatment

Why this study was terminated
Study terminated early due to low enrollment. No data collected.
Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

Herniated disc sometimes cause back pain radiating down to a leg. This pain can be so severe that it is functionally disabling. The purpose of this randomized clinical trial is to determine if corticosteroid medication, delivered directly to the area near the herniated disc, can improve the pain and functional disability associated with a herniated disc.

02

Conditions studied

  • Disc Herniation
  • Lumbosacral Radiculopathy

Keywords

  • Disc herniation
  • Lumbosacral radiculopathy
  • Corticosteroids
03

In context

Intervertebral Disc Displacement

478 studies on the registry are indexed under Intervertebral Disc Displacement; 104 are open to participants now.

This study's enrollment of 1 is below the median of 63 across 344 interventional studies indexed under Intervertebral Disc Displacement.

Browse Intervertebral Disc Displacement studies →

Lead sponsor

Montefiore Medical Center is the lead sponsor of 402 studies on the registry; 70 are open to participants now.

Of its 81 completed or terminated interventional studies of FDA-regulated products, 73 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults \<60y
  • \< 1m of symptoms
  • Symptoms consistent with herniated disc
  • MRI demonstrates corresponding disc
  • Back pain resulting in functional disability

Exclusion criteria

Exclusion Criteria:

  • Chronic pain
  • Daily pain medication
  • Frequent back pain
  • On the job injury
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    CT-guided intervention

    CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care

    Drug: CT-guided corticosteroid+ bupivicaine

  • Active comparator
    Standard medical care

    Drug: Standard medical care

Interventions

  • DrugCT-guided corticosteroid+ bupivicaine

    CT-guided corticosteroid+ bupivicaine Also get standard medical care

  • DrugStandard medical care

    Naproxen + Oxycodone/ Acetaminophen

06

What researchers measure

Primary outcomes

  1. Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire

    The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a "yes" or "no". The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score. The calculated mean and associated confidence interval values have been verified by staff statisticians.

    Time frame: Baseline and one week after emergency department discharge

Secondary outcomes

  1. Functional Disability Assessed Using Roland-Morris Scale

    The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a "yes" or "no". The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, increasing functional disability.

    Time frame: 1 month

  2. Adverse Events

    Any adverse events since randomization. %s will be compared between groups

    Time frame: 1 week after discharge from emergency department

07

Results

Posted Jun 1, 2018

Participant flow

Participant flow — Overall Study
MilestoneCT-guided InterventionStandard Medical Care
Started10
Completed00
Not completed10
Withdrew: Study terminated. no data collected.10

Outcome measures

PrimaryChange in Functional Impairment as Measured by the Roland Morris Disability Questionnaire

The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a "yes" or "no". The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score. The calculated mean and associated confidence interval values have been verified by staff statisticians.

Time frame:
Baseline and one week after emergency department discharge

No measurements were reported for this outcome.

SecondaryFunctional Disability Assessed Using Roland-Morris Scale

The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a "yes" or "no". The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, increasing functional disability.

Time frame:
1 month

No measurements were reported for this outcome.

SecondaryAdverse Events

Any adverse events since randomization. %s will be compared between groups

Time frame:
1 week after discharge from emergency department

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CT-guided Intervention———
Standard Medical Care———

Baseline characteristics

No data collected or analyzed because this study was terminated early due to low enrollment.

Age, Continuous
Age, ContinuousCT-guided InterventionStandard Medical CareTotal
Sex: Female, Male
Sex: Female, MaleCT-guided InterventionStandard Medical CareTotal
Female———
Male———
Race and Ethnicity Not Collected
Race and Ethnicity Not CollectedCT-guided InterventionStandard Medical CareTotal
Region of Enrollment
Region of Enrollment(participants)CT-guided InterventionStandard Medical CareTotal
08

Study locations

1 site
  • Montefiore Medical Center
    Bronx, New York 10467, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01267825
Lead sponsor
Montefiore Medical Center
Responsible party
Benjamin W. Friedman, MD (Prof. Emergency Medicine, Montefiore Medical Center) — Principal investigator
First posted
Dec 29, 2010
Start date
Sep 1, 2010
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Jun 1, 2018
Last update
Aug 31, 2018

Study contacts

Todd Miller, MD
principal investigator · Montefiore Medical Center
Benjamin W. Friedman, MD, MS
principal investigator · Montefiore Medical Center/Albert Einstein College of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion